CaseyL.C.. Immunologic response to infection and its role in septic shock.Crit Care Clin2000; 16: 193–213.
2.
BeutlerB., PoltorakA.. Sepsis and evolution of the innate immune response.Crit Care Med2001; 29(Suppl): S2–S6.
3.
KrishnaswamyG., KelleyJ., YerraL., SmithJ.K., ChiD.S.. Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease.J Interferon Cytokine Res1999; 19: 91–104.
4.
AirdW.C.. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome.Blood2003; 101: 3765–77.
5.
LeviM., ten CateH., van der PollT., van DeventerS.J.. Pathogenesis of disseminated intravascular coagulation in sepsis.JAMA1993; 270: 975–9.
6.
DellingerR.P.. Cardiovascular management of septic shock.Crit Care Med2003; 31: 946–55.
7.
BoneR.C., BalkR.A., CerraF.B., DellingerR.P., FeinA.M., KnausW.A., ScheinR.M., SibbaldW.J.. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.Chest1992; 101: 1644–55.
AngusD., Linde-ZwirbleW.T., LidickerJ., ClermontG., CarcilloJ., PinskyM.R.. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care.Crit Care Med2001; 29: 1303–10.
10.
EsmonC.T.. The protein C anticoagulant pathway.Arterioscler Thromb1992; 12: 135–45.
11.
MarlarR.A., KleissA.J., GriffinJ.H.. Human protein C: Inactivation of factors V and VIII in plasma by the activated molecule.Ann N Y Acad Sci1981; 370: 303–10.
12.
GruberA., HansonS.R., KellyA.B., YanB.S., BangN., GriffinJ.H., HarkerL.A.. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis.Circulation1990; 82: 578–5.
13.
SakataY., CurridenS., LawrenceD., GriffinJ.H., LoskutoffD.J.. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity.Proc Natl Acad Sci USA1985; 82: 1121–5.
14.
van HinsberghV.W., BertinaR.M., van WijngaardernA., van TilburgN.H., EmeisJ.J., HaverkateF.. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium.Blood1985; 65: 444–51.
15.
EsmonC.T.. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway.J Autoimmun2000; 15: 113–6.
16.
MosnierL.O., GriffinJ.H.. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor.Biochem J2003; 373: 65–70.
17.
LaszikZ., MitroA., TaylorF.B.Jr., FerrellG., EsmonC.T.. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway.Circulation1997; 96: 3633–40.
18.
SturnD.H., KaneiderN.C., FeistritzerC., DjananiA., FukudomeK., WiedermannC.J.. Expression and function of the endothelial protein C receptor in human neutrophils.Blood2003; 102: 1499–505.
19.
HancockW.W., GreyS.T., HauL., AkalinE., OrthnerC., SayeghM.H., SalemH.H.. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses.Transplantation1995; 60: 1525–32.
20.
FeistritzerC., SturnD.H., KaneiderN.C., DjananiA., WiedermannC.J.. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C.J Allergy Clin Immunol2003; 112: 375–81.
21.
ShimizuS., GabazzaE.C., TaguchiO., YasuiH., TaguchiY., HayashiT., IdoM., ShimizuT., NakagakiT., KobayashiH., FukudomeK., TsuneyoshiN., D'Alessandro-GabazzaC.N., IzumizakiM., IwaseM., HommaI., AdachiY., SuzukiK.. Activated protein C inhibits the expression of platelet-derived growth factor in the lung.Am J Respir Crit Care Med2003; 167: 1416–26.
22.
FisherC.J.Jr., YanS.B.. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases.Crit Care Med2000; 28(Suppl): S49–56.
23.
BernardG.R., VincentJ.L., LaterreP.F., LaRosaS.P., DhainautJ.F., Lopez-RodriguezA., SteingrubJ.S., GarberG.E., HelterbrandJ.D., ElyE.W., FisherC.J.Jr.. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis.N Engl J Med2001; 344: 699–709.
24.
YanS.B., DhainautJ.F.. Activated protein C versus protein C in severe sepsis.Crit Care Med2001; 29(Suppl): S69–74.
25.
DellingerR.P., ParrilloJ.E.. Mediator modulation therapy of severe sepsis and septic shock: Does it work?Crit Care Med2004; 32: 282–6.
26.
AttarS., MansbergerA.R.Jr., IraniB., KirbyW.Jr., MasaitisC., CowleyR.A.. Coagulation changes in clinical shock. II. Effect of septic shock on clotting times and fibrinogen in humans.Ann Surg1966; 164: 41–50.
CorriganJ.J.Jr., RayW.L., MayN.. Changes in the blood coagulation system associated with septicemia.N Engl J Med1968; 279: 851–6.
29.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, for the KyberSept Trial Study Group.Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.JAMA2001; 286: 1869–78.
30.
Abraham E, Reinhart K, Opal S, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, the OPTIMIST Trial Study Group.Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial.JAMA2003; 290: 238–47.
31.
WalkerF.J.. Regulation of bovine activated protein C by protein S: The role of the cofactor protein in species specificity.Thromb Res1981; 22: 321–7.
32.
WeinsteinR.E., WalkerF.J.. Species specificity of the fibrinolytic effects of activated protein C.Thromb Res1991; 63: 123–31.
33.
WeinsteinR.E., WalkerF.J.. Effect of rabbit activated protein C on thrombin generation and fibrinolysis in a species-specific in vivo model: effect of modulation of protein S activity.Semin Thromb Haemost1993; 19: 368–77.
34.
HeX., DahlbackB.. Rabbit plasma, unlike its human counterpart, contains no complex between protein S and C4b-binding protein.Thromb Haemost1994; 71: 446–51.
35.
HollyR.D., FosterD.C.. Resistance to inhibition by alpha-1-anti-trypsin and species specificity of a chimeric human/bovine protein C.Biochemistry1994; 33: 1876–80.
36.
TaylorF.B.Jr., ChangA., EsmonC.T., D'AngeloA., Vigano-D'AngeloS., BlickK.E.. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.J Clin Invest1987; 79: 918–25.
37.
BoneR.C., FrancisP.B., PierceA.K.. Intravascular coagulation associated with the adult respiratory distress syndrome.Am J Med1976; 61: 585–9.
38.
ThijsL.G., de BoerJ.P., de GrootM.C., HackC.E.. Coagulation disorders in septic shock.Intensive Care Med1993; 19(Suppl): S8–15.
39.
FourrierF., ChopinC., GoudemandJ., HendrycxS., CaronC., RimeA., MareyA., LestavelP.. Septic shock, multiple organ failure and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C and protein S deficiencies.Chest1992; 101: 816–23.
40.
LorenteJ.A., Garcia-FradeL.J., LandinL., de PabloR., TorradoC., RenesE., Garcia-AvelloA.. Time course of hemostatic abnormalities in sepsis and its relation to outcome.Chest1993; 103: 1536–42.
41.
PowarsD., LarsenR., JohnsonJ., HulbertT., SunT., PatchM.J., FrancisR., ChanL.. Epidemic meningococcemia and purpura fulminans with induced protein C deficiency.Clin Infect Dis1993; 17: 254–61.
42.
BransonH.E., KatzJ., MarbleR., GriffinJ.H.. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant.Lancet1983; 2: 1165–8.
43.
HartmanK.R., Manco-JohnsonM., RawlingsJ.S., BowerD.J., MarlarR.A.. Homozygous protein C deficiency: early treatment with warfarin.Am J Pediatr Hem Oncol1989; 11: 395–401.
44.
DreyfusM., MagnyJ.F., BrideyF., SchwarzH.P., PlancheC., DehanM., TcherniaG.. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate.N Engl J Med1991; 325: 1565–8.
45.
GersonW.T., DickermanJ.D., BovillE.G., GoldenE.. Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate.Pediatrics1993; 91: 418–22.
46.
EsmonC.T.. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface.FASEB J1995; 9: 946–55.
47.
EsmonC.T.. Molecular events that control the protein C anticoagulant pathway.Thromb Haemost1993; 70: 29–35.
48.
HansonS.R., GriffinJ.H., HarkerL.A., KellyA.B., EsmonC.T., GruberA.. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.J Clin Invest1993; 92: 2003–12.
49.
GruberA., PalA., KissR.G., SasG., GriffinJ.H.. Generation of activated protein C during thrombolysis.Lancet1993; 342: 1275–6.
50.
ParentC., EichackerP.Q.. Neutrophil and endothelial cell interactions in sepsis. The role of adhesion molecules.Infect Dis Clin N Am1999; 13: 427–47.
51.
MooreK.L., AndreoliS.P., EsmonN.L., EsmonC.T., BangN.U.. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro.J Clin Invest1987; 79: 124–30.
52.
MooreK.L., EsmonC.T., EsmonN.L.. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture.Blood1989; 73: 159–65.
53.
MacGregorI.R., PerrieM., DonnellyS.C., HaslettC.. Modulation of human endothelial thrombomodulin by neutrophils and their release products.Am J Respir Crit Care Med1997; 155: 47–52.
54.
FaustS.N., LevinM., HarrisonO.B., GoldinR.D., LockhartM.S., KondaveetiS., LaszikZ., EsmonC.T., HeydermanR.S.. Dysfunction of endothelial protein C activation in severe meningococcal sepsis.N Engl J Med2001; 345: 408–16.
55.
BernardG.R., ElyE.W., WrightT.J., FraizJ., StasekJ.E.Jr., RussellJ.A., MayersI., RosenfeldB.A., MorrisP.E., YanS.B., HelterbrandJ.D.. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.Crit Care Med2001; 29: 2051–9.
56.
MaciasW.L., DhainautJ.F., YanS.C., HelterbrandJ.D., SegerM., JohnsonG3rd, SmallD.S.. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.Clin Pharmacol Ther2002; 72: 391–402.
57.
PhilapitschA., SchwarzH.P.. The effect of leukocyte elastase on protein C and activated protein C (Abstract 664).Thromb Haemost1993; 69: 726.
58.
DhainautJ.F., MarinN., MignonA., VinsonneauC.. Hepatic response to sepsis: interaction between coagulation and inflammatory processes.Crit Care Med2001; 29(Suppl): S42–7.
59.
de KleijnE.D., de GrootR., HackC.E., MulderP.G., EnglW., MoritzB., JoostenK.F., HazelzetJ.A.. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blind, placebo-controlled, dose-finding study.Crit Care Med2003; 31: 1839–47.
60.
ElyE.W., LaterreP.F., AngusD.C., HelterbrandJ.D., LevyH., DhainautJ.F., VincentJ.L., MaciasW.L., BernardG.R.; PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.Crit Care Med2003; 31: 12–9.
61.
VincentJ.L., AngusD.C., ArtigasA., KalilA., BassonB.R., JamalH.H., JohnsonG3rd, BernardG.R., for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.Crit Care Med2003; 31: 834–40.
62.
BernardG.R., MaciasW.L., JoyceD.E., WilliamsM.D., BaileyJ., VincentJ.L.. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.Crit Care2003; 7: 155–63.
63.
KastenbauerS., PfisterH.W.. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases.Brain2003; 126: 1015–25.
64.
BuschC., CancillaP.A., DeBaultL.E., GoldsmithJ.C., OwenW.G.. Use of endothelium cultured on microcarriers as a model for the microcirculation.Lab Invest1982; 47: 498–504.
65.
EsmonC.T.. The endothelial protein C receptor.Thromb Haemost2000; 83: 639–43.
66.
RiewaldM., PetrovanR.J., DonnerA, HulbertT., SunT., PatchM.J., FrancisR., ChanL.. Activation of endothelial cell protease activated receptor 1 by the protein C pathway.Science2002; 296: 1880–2.
67.
GreyS.T., TsuchidaA., HauH., OrthnerC.L., SalemH.H., HancockW.W.. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.J Immunol1994; 153: 3664–72.
68.
JoyceD.E., GelbertL., CiacciaA., DeHoffB., GrinnellB.W.. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis.J Biol Chem2001; 276: 11199–203.
69.
LinderR., FrebeliusS., JanssonK., SwedenborgJ.. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.Blood Coagul Fibrinolysis2003; 14: 139–46.
70.
DhainautJ.F., YanS.B., MargolisB.D., LorenteJ.A., RussellJ.A., FreebairnR.C., SpapenH.D., RiessH., BassonB., JohnsonG3rd, KinasewitzG.T., for the PROWESS Sepsis Study Group. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.Thromb Haemost2003; 90: 642–53.
71.
DerhaschnigU., ReiterR., KnoblP., BaumgartnerM., KeenP., JilmaB.. Recombinant human activated protein C (rhAPC; drotrecogin alfa (activated)) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.Blood2003; 102: 2093–8.
72.
KalilA.C., CoyleS.M., UmJ.Y., LaRosaS.P., TurloM.A., CalvanoS.E., SundinD.P., NelsonD.R., LowryS.F.. Effects of drotrecogin alfa (activated) in human endotoxemia.Shock2004; 21: 222–9.
73.
Manco-JohsonM.J., Knapp-ClevengerR.. Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency.J Pediatr Hematol Oncol2004; 26: 25–7.
74.
RiversE., NguyenB., HavstadS., ResslerJ., MuzzinA., KnoblichB., PetersonE., TomlanovichM., Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock.N Engl J Med2001; 345: 1368–77.
75.
Garnacho-MonteroJ., Garcia-GarmendiaL., Barrero-AlmodovarA., Jimenez-JimenezF.J., Perez-ParedesC., Ortiz-LeybaC.. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.Crit Care Med2003; 31: 2742–51.
76.
AnnaneD., SebilleV., CharpentierC., BollaertP.E., FrancoisB., KorachJ.M., CapellierG., CohenY., AzoulayE., TrocheG., Chaumet-RiffautP., BellissantE.. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.JAMA2002; 288: 862–71.
77.
AnnaneD., BriegelJ., KehD., MorenoR., SingerM., SprungC.L.; Corticus Study Coordinators. Clinical equipoise remains for issues of adrenocorticotropic hormone administration, cortisol testing, and therapeutic use of hydrocortisone.Crit Care Med2003; 31: 2250–1.
78.
van den BergheG., WoutersP., WeekersF., VerwaestC., BruyninckxF., SchetzM., VlasselaersD., FerdinandeP., LauwersP., BouillonR.. Intensive insulin therapy in the critically ill patients.N Engl J Med2001; 345: 1359–67.
